VarmX

All Fund articles Fund PR Portfolio articles Portfolio PR

VarmX recognised with two prestigious industry award nominations

2026.09.222026.09.22 / Nominated for the 2026 Prix Galien USA “Best Startup” Award, and shortlisted with partner CSL for “Deal of the Year” at the 2026 European Lifestars Awards Leiden, The Netherlands, 15 Septemb ...

VarmX enrols first participant in global Phase 3 EquilibriX-S trial evaluating VMX-C001 in urgent surgery

2026.08.202026.08.20 / • First participant enrolled: EquilibriX-S (NCT07288489), a landmark registrational Phase 3 study of VMX-C001 vs usual pharmacologic care in patients taking FXa inhibitors who require an urgent surge ...

VarmX announces publication of sensitive coagulation assays to assess restoration of coagulation using VMX-C001 in the presence of Factor Xa inhibitors

2026.02.252026.02.25 / Key highlights The collaborative study with Coagulation Profile BV, Maastricht University and Leiden University Medical Center has been accepted for publication in Research and Practice in Thromb ...

VarmX receives Phase 1 waiver from Japanese regulator PMDA

2025.09.252025.09.25 / for lead asset VMX-C001 Japanese regulator, the PMDA, waived the requirement for a Phase 1 trial in Japanese subjects for lead asset VMX-C001, enabling it to go straight to Phase 3 development ...

VarmX partners with CSL in a strategic collaboration and option agreement to develop novel investigational coagulation treatment

2025.09.162025.12.02 / Full funding of VMX-C001 Phase 3 trial, late-stage product development, manufacturing and pre-launch activities VarmX shareholders to receive initial $117m upfront and further potential milestone ...

VarmX receives IND approval for Phase 3 trial of VMX-C001 in Urgent Surgery

2025.07.092025.09.22 / Enables initiation of global EquilibriX-S trial later this year Critical milestone in development of novel bypass agent to restore coagulation, enabling urgent surgery in patients taking a ...

VarmX announces appointment of John Glasspool as CEO

2024.11.122025.04.30 / Leadership team fully strengthened to drive next phase of development Leiden, The Netherlands, 12 november 2024 VarmX, a biotech company developing innovative approaches for the bypass of direc ...

VarmX raises €30 million Series B2 financing for IND approvaland preparations for pivotal trial

2023.05.252024.05.13 / Sound Bioventures and EIC Fund join existing investors EQT Life Sciences (formerly LSP),Inkef, Lundbeckfonden BioCapital, Ysios Capital, BioGeneration Ventures, InnovationQuarter and Libertatis Ergo ...

From toxin to remedy, and operating room to the boardroom

2023.03.212025.12.02 / Even though it’s based on venom from one of the deadliest snakes in the world, the lead product of biotech startup VarmX can be life-saving for patients on blood thinners. It's an unexpected turn, bu ...